Universität zu Köln

2020

Fraser, Graeme, Chanan-Khan, Asher, Demirkan, Faith, Silva, Rodrigo Santucci, Grosicki, Sebastian, Janssens, Ann, Mayer, Jiri, Bartlett, Nancy, Dilhuydy, Marie Sarah, Loscertales, Javier, Avigdor, Abraham, Rule, Simon, Samoilova, Olga, Pavlosky, Miguel, Hallek, Michael, Salman, Mariya, Tamegnon, Monelle, Sun, Steven, Connor, Anne, Nottage, Kerri, Balasubramanian, Sriram, Howes, Angela and Cramer, Paula (2020). Final 5-year updated results from a phase 3 study (HELIOS) of ibrutinib plus bendamustine and rituximab (BR) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Leuk. Lymphoma, 61. S. 106 - 109. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

2017

Hallek, Michael, Fraser, Graeme, Cramer, Paula, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Silva, Rodrigo Santucci, Grosicki, Sebastian, Janssens, Ann, Pristupa, Aleksander, Mayer, Jiri, Dilhuydy, Marie Sarah, Loscertales, Javier, Bartlett, Nancy, Avigdor, Abraham, Rule, Simon, Sun, Steven, Mahler, Michelle, Phelps, Charles, Salman, Mariya, Howes, Angela and Chanan-Khan, Asher (2017). Three-year follow-up of patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) receiving ibrutinib plus bendamustine and rituximab (BR) versus placebo plus BR: an update of the HELIOS study. Leuk. Lymphoma, 58. S. 192 - 195. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Kipps, Thomas J., Mahler, Michelle, Fraser, Graeme, Coutre, Steven, Brown, Jennifer, Barrientos, Jacqueline, Barr, Paul ORCID: 0000-0002-9733-401X, Byrd, John C., O'Brien, Susan, Dilhuydy, Marie Sarah, Jaeger, Ulrich, Moreno, Carol, Cramer, Paula, Stilgenbauer, Stephan, Chanan-Khan, Asher, Salman, Mariya, Cheng, Mei, Londhe, Anil, Ninomoto, Joi, Howes, Angela, James, Danelle, Hallek, Michael and Hillmen, Peter (2017). Outcomes of ibrutinib-treated patients with chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) with high-risk prognostic factors in an integrated analysis of 3 randomized phase 3 studies. Leuk. Lymphoma, 58. S. 10 - 13. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

2015

Chanan-Khan, Asher, Cramer, Paula, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Fraser, Graeme, Silva, Rodrigo Santucci, Pylypenko, Halyna, Grosicki, Sebastian, Janssens, Ann, Pristupa, Aleksander, Goy, Andre ORCID: 0000-0001-5125-6522, Mayer, Jiri, Dilhuydy, Marie Sarah, Loscertales, Javier, Bartlett, Nancy L., Avigdor, Abraham, Rule, Simon, Sun, Steven, Phelps, Charles, Mahler, Michelle, Salman, Mariya, Howes, Angela and Hallek, Michael (2015). Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Chanan-Khan, Asher, Cramer, Paula, Fraser, Graeme, Silva, Rodrigo Santucci, Grosicki, Sebastian, Pristupa, Aleksander, Dilhuydy, Marie Sarah, Goy, Andre ORCID: 0000-0001-5125-6522, Mato, Anthony R., Damle, Rajendra, Phelps, Charles, Mahler, Michelle, Salman, Mariya, Schaffer, Michael, Howes, Angela and Balasubramanian, Sriram (2015). Impact of High Risk Prognostic Parameters and Addition of Ibrutinib to Bendamustine/Rituximab (BR) on Outcomes for Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) from the Phase 3 Double-Blind HELIOS Trial. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Cramer, Paula, Chanan-Khan, Asher, Fraser, Graeme, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Silva, Rodrigo Santucci, Pylypenko, Halyna, Grosicki, Sebastian, Janssens, Ann, Goy, Andre ORCID: 0000-0001-5125-6522, Mayer, Jiri, Dilhuydy, Marie Sarah, Loscertales, Javier, Bartlett, Nancy L., Avigdor, Abraham, Rule, Simon, Sun, Steven, Phelps, Charles, Mahler, Michelle, Salman, Mariya, Schaffer, Michael, Balasubramanian, Sriram, Howes, Angela and Hallek, Michael (2015). Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Traina, Shana, Fraser, Graeme, Cramer, Paula, Silva, Rodrigo Santucci, Grosicki, Sebastian, Dilhuydy, Marie Sarah, Mahler, Michelle, Salman, Mariya and Howes, Angela (2015). Ibrutinib Plus Bendamustine/Rituximab (BR) Is Associated with Greater Reductions in Fatigue Than Placebo Plus BR Among Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and Fatigue. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020